Our top RSV content of 2025 included how nirsevimab and clesrovimab changed RSV prevention among younger patients, as well as ...
Here are the top 5 inflammation pieces of 2025; stay up-to-date with all the inflammation content from The American Journal ...
Although frontline maintenance treatment with fuzuloparib monotherapy produced a progression-free survival (PFS) benefit in patients with newly diagnosed advanced ovarian cancer, the addition of ...
Discover the latest breakthroughs in myasthenia gravis treatment, including rozanolixizumab and nipocalimab, and insights on ...
Our content coverage from the Southeastern Educational Congress of Optometry (SECO) 2025 provided information on a mix of ...
Here are the top 5 ovarian cancer articles of 2025; stay up-to-date with all the ovarian cancer content from The American ...
The top Managed Care Cast episodes explored wellness visits, weight loss drug access, neurospine care, public health policy, ...
Oral roflumilast showed potential as a nonbiologic systemic therapy for moderate to severe psoriasis, offering an alternative ...
The 2025 pharmaceutical pipeline is expanding with generics, biosimilars, and new therapies, despite delays from patent ...
The GLOVe regimen, combining glofitamab, lenalidomide, and venetoclax, shows rapid and deep responses in high-risk MCL ...
The top 5 infectious disease stories on AJMC.com this year covered both outbreaks and government-related developments. Bird ...
Key Takeaways. TTP following R-CHOP is a strong prognostic factor for survival in R/R DLBCL, with shorter TTP linked to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results